You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimum Dose of rhCC10 for Lung Protection in IRDS

    SBC: CLARAGEN, INC.            Topic: N/A

    DESCRIPTION (Scanned from the applicant's description): The proposed study involves an evaluation of the dose response to recombinant human CC10 in the preterm lamb, a surfactant-dependent model of neonatal/infant respiratory distress syndrome (IRDS). The preterm lamb model was used in the clinical development of artificial surfactants for the treatment of I ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. NOVEL METHOD FOR ENHANCEMENT OF IABC CARDIAC ASSISTANCE

    SBC: FLUENT CARDIOVASCULAR SOLUTIONS, INC.            Topic: N/A

    We have developed certain concepts for the design and operation of an novel skewed Intra-Aortic Balloon Counterpulsation (IABC) device that is capable of providing cardiac assistance with significantly lower regurgitant losses and viscous stresses in the blood flow. As a result, the ventricular afterload pressure is reduced, thereby providing optimal and enhanced cardiac-assist. Specifically, in t ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. ANTIMETASTATIC EFFECT OF THROMBOSPONDIN DERIVED PEPTIDES

    SBC: INKINE PHARMACEUTICAL COMPANY            Topic: N/A

    DESCRIPTION: The long term objective is to demonstrate the efficacy, safety, and cost-effectiveness of thrombospondin-I (TSP-I) peptides containing the CSVTCG sequence or mimetics, either alone or in combination with other agents, to treat cancer metastasis. ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. Preparation of a Quantitative Apoptosis Imaging Agent

    SBC: NAVISCAN PET SYSTEMS, INC.            Topic: N/A

    This proposal addresses development of new imaging technology for noninvasive quantitative measurement of apoptosis in vivo. Apoptosis is genetically defined cell death. Understanding the role of apoptosis is critical to the development of new molecular-based therapeutic modalities. An apoptosis-imaging agent could be used to modify therapy for cancer patients, and to monitor cardiac transplant pa ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Vaccine for Cancer

    SBC: ONCOVAX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of Oncovax, LLC is to translate a novel vaccine strategy that we have developed into a precise and cost-effective methodology that is marketable for vaccination against a broad array of human tumors. Our vaccine strategy targets oncogenes that are overexpressed in tumor cells. The goal of work proposed here is to investigate a ne ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Development of basic tools for Cancer Research

    SBC: PROTEIN RESEARCH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to produce active recombinant proteins involved in cancer progression and other important cellular processes. Recombinant proteins in biomedical research have now become an essential tool to study many aspects of cellular biology. Genes coding for several important cellular function such as tumor suppres ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid, Accurate, and Low-Cost Stool Clostridium difficile Genetic Test

    SBC: LENIMA FIELD DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Clostridium difficile (CD) is a bacterium causing diarrhea and other intestinal problems linked to 14,000 annual deaths in the US. CDI is an antibiotic-associated infection as well as a health-care-associated infection.Current CDI diagnosis relies on CD toxins enzyme immunoassay (EIA) together with antigen (GDH) EIA. Although stool toxin EIA is specific and rel ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government